Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase ...
The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase ...